SEARCH

SEARCH BY CITATION

References

  • Abraham, E., Reinhart, K., Svoboda, P., Seibert, A., Olthoff, D., Dal Nogare, A., Postier, R., Hempelmann, G., Butler, T., Martin, E., Zwingelstein, C., Percell, S., Shu, V., Leighton, A. & Creasey, A.A. (2001) Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Critical Care Medicine, 29, 20812089.
  • Abraham, E., Reinhart, K., Opal, S., Demeyer, I., Doig, C., Rodriguez, A.L., Beale, R., Svoboda, P., Laterre, P.F., Simon, S., Light, B., Spapen, H., Stone, J., Seibert, A., Peckelsen, C., De Deyne, C., Postier, R., Pettila, V., Artigas, A., Percell, S.R., Shu, V., Zwingelstein, C., Tobias, J., Poole, L., Stolzenbach, J.C. & Creasey, A.A. (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA, 290, 238247.
  • Abraham, E., Laterre, P.F., Garg, R., Levy, H., Talwar, D., Trzaskoma, B.L., Francois, B., Guy, J.S., Bruckmann, M., Rea-Neto, A., Rossaint, R., Perrotin, D., Sablotzki, A., Arkins, N., Utterback, B.G. & Macias, W.L. (2005) Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. New England Journal of Medicine, 353, 13321341.
  • Akca, S., Haji-Michael, P., De, M.A., Suter, P., Levi, M. & Vincent, J.L. (2002) Time course of platelet counts in critically ill patients. Critical Care Medicine, 30, 753756.
  • Al-Mondhiry, H. (1975) Disseminated intravascular coagulation: experience in a major cancer center. Thrombosis et Diathesis Haemorrhagica, 34, 181193.
  • Angstwurm, M.W., Dempfle, C.E. & Spannagl, M. (2006) New disseminated intravascular coagulation score: a useful tool to predict mortality in comparison with acute physiology and chronic health evaluation II and logistic organ dysfunction scores. Critical Care Medicine, 34, 314320.
  • Asakura, H., Ontachi, Y., Mizutani, T., Kato, M., Ito, T., Saito, M., Morishita, E., Yamazaki, M., Aoshima, K., Takami, A., Yoshida, T., Suga, Y., Miyamoto, K. & Nakao, S. (2001) Decreased plasma activity of antithrombin or protein C is not due to consumption coagulopathy in septic patients with disseminated intravascular coagulation. European Journal of Haematology, 67, 170175.
  • Audibert, G., Lambert, H., Toulemonde, F., Alexandre, P., Laprevote-Heully, M.C., Bollaert, P.E., Bauer, P. & Larcan, A. (1987) Use of a low molecular weight heparin, CY 222, in the treatment of consumption coagulopathy. Journal des Maladies Vasculaires, 12 (Suppl B), 147151 [French].
  • Avvisati, G., Ten Cate, J.W., Buller, H.R. & Mandelli, F. (1989) Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet, 2, 122124.
  • Bakhtiari, K., Meijers, J.C., De, J.E. & Levi, M. (2004) Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Critical Care Medicine, 32, 24162421.
  • Bernard, G.R., Vincent, J.L., Laterre, P.F., LaRosa, S.P., Dhainaut, J.F., Lopez-Rodriguez, A., Steingrub, J.S., Garber, G.E., Helterbrand, J.D., Ely, E.W. & Fisher, C.J.J. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. New England Journal of Medicine, 344, 699709.
  • Bernard, G.R., Macias, W.L., Joyce, D.E., Williams, M.D., Bailey, J. & Vincent, J.L. (2003) Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Critical Care, 7, 155163.
  • Bernard, G.R., Margolis, B.D., Shanies, H.M., Ely, E.W., Wheeler, A.P., Levy, H., Wong, K. & Wright, T.J. (2004) Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest, 125, 22062216.
  • Bick, R.L. (1996) Disseminated intravascular coagulation: objective clinical and laboratory diagnosis, treatment, and assessment of therapeutic response. Seminars in Thrombosis & Hemostasis, 22, 6988.
  • Bick, R.L. & Baker, W.F. (1992) Diagnostic efficacy of the D-dimer assay in disseminated intravascular coagulation (DIC). Thrombosis Research, 65, 785790.
  • Boisclair, M.D., Ireland, H. & Lane, D.A. (1990) Assessment of hypercoagulable states by measurement of activation fragments and peptides. Blood Reviews, 4, 2540.
  • Brown, J.E., Olujohungbe, A., Chang, J., Ryder, W.D., Morganstern, G.R., Chopra, R. & Scarffe, J.H. (2000) All-trans retinoic acid (ATRA) and tranexamic acid: a potentially fatal combination in acute promyelocytic leukaemia. British Journal of Haematology, 110, 10101012.
  • Carr, J.M., McKinney, M. & McDonagh, J. (1989) Diagnosis of disseminated intravascular coagulation. Role of D-dimer. American Journal of Clinical Pathology, 91, 280287.
  • Cauchie, P., Cauchie, C., Boudjeltia, K.Z., Carlier, E., Deschepper, N., Govaerts, D., Migaud-Fressart, M., Woodhams, B. & Brohee, D. (2006) Diagnosis and prognosis of overt disseminated intravascular coagulation in a general hospital – meaning of the ISTH score system, fibrin monomers, and lipoprotein-C-reactive protein complex formation. American Journal of Hematology, 81, 414419.
  • Collins, P.W., Macchiavello, L.I., Lewis, S.J., Macartney, N.J., Saayman, A.G., Luddington, R., Baglin, T. & Findlay, G.P. (2006) Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls. British Journal of Haematology, 135, 220227.
  • Conway, E.M. & Rosenberg, R.D. (1988) Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Molecular and Cellular Biology, 8, 55885592.
  • Cook, D.J., Crowther, M.A., Meade, M.O. & Douketis, J. (2005) Prevalence, incidence, and risk factors for venous thromboembolism in medical-surgical intensive care unit patients. Journal of Critical Care, 20, 309313.
  • Corrigan, J.J.J. & Jordan, C.M. (1970) Heparin therapy in septicemia with disseminated intravascular coagulation. New England Journal of Medicine, 283, 778782.
  • De Pont, A.C., Bakhtiari, K., Hutten, B.A., De Jonge, E., Vroom, M.B., Meijers, J.C., Buller, H.R. & Levi, M. (2005) Recombinant human activated protein C resets thrombin generation in patients with severe sepsis – a case control study. Critical Care, 9, R490R497.
  • Dempfle, C.E., Zips, S., Ergul, H. & Heene, D.L. (2001) The fibrin assay comparison trial (FACT): correlation of soluble fibrin assays with D-dimer. Journal of Thrombosis and Haemostasis, 86, 12041209.
  • Dempfle, C.E., Wurst, M., Smolinski, M., Lorenz, S., Osika, A., Olenik, D., Fiedler, F. & Borggrefe, M. (2004a) Use of soluble fibrin antigen instead of D-dimer as fibrin-related marker may enhance the prognostic power of the ISTH overt DIC score. Journal of Thrombosis and Haemostasis, 91, 812818.
  • Dempfle, C.E., Lorenz, S., Smolinski, M., Wurst, M., West, S., Houdijk, W.P., Quintel, M. & Borggrefe, M. (2004b) Utility of activated partial thromboplastin time waveform analysis for identification of sepsis and overt disseminated intravascular coagulation in patients admitted to a surgical intensive care unit. Critical Care Medicine, 32, 520524.
  • Dhainaut, J.F., Yan, S.B., Joyce, D.E., Pettila, V., Basson, B.R., Brandt, J.T., Sundin, D. & Levi, M. (2004) Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis, 2, 19241933.
  • Downey, C., Kazmi, R. & Toh, C.H. (1997) Novel and diagnostically applicable information from optical waveform analysis of blood coagulation in disseminated intravascular coagulation. British Journal of Haematology, 98, 6873.
  • Downey, C., Kazmi, R. & Toh, C.H. (1998) Early identification and prognostic implications in disseminated intravascular coagulation through transmittance waveform analysis. Journal of Thrombosis and Haemostasis, 80, 6569.
  • Faust, S.N., Levin, M., Harrison, O.B., Goldin, R.D., Lockhart, M.S., Kondaveeti, S., Laszik, Z., Esmon, C.T. & Heyderman, R.S. (2001) Dysfunction of endothelial protein C activation in severe meningococcal sepsis. New England Journal of Medicine, 345, 408416.
  • Feinstein, D.I. (1988) Treatment of disseminated intravascular coagulation. [Review] [122 refs]. Seminars in Thrombosis & Hemostasis, 14, 351362.
  • Fourrier, F., Chopin, C., Goudemand, J., Hendrycx, S., Caron, C., Rime, A., Marey, A. & Lestavel, P. (1992) Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest, 101, 816823.
  • Gando, S., Wada, H., Asakura, H., Iba, T., Eguchi, Y., Okamoto, K., Ohtomo, Y., Kawasugi, K., Koga, S., Koseki, K., Tsuji, H., Mayumi, T., Murata, A., Nakagawa, M. & Endo, S. (2005) Evaluation of new Japanese diagnostic criteria for disseminated intravascular coagulation in critically ill patients. Clinical and Applied Thrombosis/Hemostasis, 11, 7176.
  • Horan, J.T. & Francis, C.W. (2001) Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation. Seminars in Thrombosis & Hemostasis, 27, 657666.
  • Kienast, J., Juers, M., Wiedermann, C.J., Hoffmann, J.N., Ostermann, H., Strauss, R., Keinecke, H.O., Warren, B.L. & Opal, S.M. (2006) Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis, 4, 9097.
  • Levi, M. (2004) Current understanding of disseminated intravascular coagulation. British Journal of Haematology, 124, 567576.
  • Levi, M. (2005) Disseminated intravascular coagulation: what’s new? Critical Care Clinics, 21, 449467.
  • Levi, M. & Opal, S.M. (2006) Coagulation abnormalities in critically ill patients. Critical Care, 10, 222.
  • Levi, M. & Ten, C.H. (1999) Disseminated intravascular coagulation. New England Journal of Medicine, 341, 586592.
  • Levi, M., De, J.E., Van Der, P.T. & Ten, C.H. (1999) Disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis, 82, 695705.
  • Levi, M., Levy, M., Williams, M.D., Douglas, I., Artigas, A., Antonelli, M., Wyncoll, D., Janes, J., Booth, F.V., Wang, D., Sundin, D.P. & Macias, W.L. (2007) Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). American Journal of Respiratory and Critical Care Medicine, 176, 483490.
  • Mackie, I.J., Kitchen, S., Machin, S.J. & Lowe, G.D. (2003) Guidelines on fibrinogen assays. British Journal of Haematology, 121, 396404.
  • Mannucci, P.M. & Levi, M. (2007) Prevention and treatment of major blood loss. New England Journal of Medicine, 356, 23012311.
  • Mant, M.J. & King, E.G. (1979) Severe, acute disseminated intravascular coagulation. A reappraisal of its pathophysiology, clinical significance and therapy based on 47 patients. American Journal of Medicine, 67, 557563.
  • Matsumoto, T., Wada, H., Nishioka, Y., Nishio, M., Abe, Y., Nishioka, J., Kamikura, Y., Sase, T., Kaneko, T., Houdijk, W.P., Nobori, T. & Shiku, H. (2006) Frequency of abnormal biphasic aPTT clot waveforms in patients with underlying disorders associated with disseminated intravascular coagulation. Clinical and Applied Thrombosis/hemostasis, 12, 185192.
  • McCarron, B.I., Marder, V.J. & Francis, C.W. (1999) Reactivity of soluble fibrin assays with plasmic degradation products of fibrin and in patients receiving fibrinolytic therapy. Journal of Thrombosis and Haemostasis, 82, 17221729.
  • Mesters, R.M., Mannucci, P.M., Coppola, R., Keller, T., Ostermann, H. & Kienast, J. (1996) Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood, 88, 881886.
  • Mongan, P.D. & Hosking, M.P. (1992) The role of desmopressin acetate in patients undergoing coronary artery bypass surgery. A controlled clinical trial with thromboelastographic risk stratification. Anesthesiology, 77, 3846.
  • Nakamura, Y., Tomura, S., Tachibana, K., Chida, Y. & Marumo, F. (1992) Enhanced fibrinolytic activity during the course of hemodialysis. Clinical Nephrology, 38, 9096.
  • Neame, P.B., Kelton, J.G., Walker, I.R., Stewart, I.O., Nossel, H.L. & Hirsh, J. (1980) Thrombocytopenia in septicemia: the role of disseminated intravascular coagulation. Blood, 56, 8892.
  • Olson, J.D., Kaufman, H.H., Moake, J., O’Gorman, T.W., Hoots, K., Wagner, K., Brown, C.K. & Gildenberg, P.L. (1989) The incidence and significance of hemostatic abnormalities in patients with head injuries. Neurosurgery, 24, 825832.
  • Patel, R., Cook, D.J., Meade, M.O., Griffith, L.E., Mehta, G., Rocker, G.M., Marshall, J.C., Hodder, R., Martin, C.M., Heyland, D.K., Peters, S., Muscedere, J., Soth, M., Campbell, N. & Guyatt, G.H. (2005) Burden of illness in venous thromboembolism in critical care: a multicenter observational study. Journal of Critical Care, 20, 341347.
  • Pernerstorfer, T., Hollenstein, U., Hansen, J., Knechtelsdorfer, M., Stohlawetz, P., Graninger, W., Eichler, H.G., Speiser, W. & Jilma, B. (1999) Heparin blunts endotoxin-induced coagulation activation. Circulation, 100, 24852490.
  • Prisco, D., Paniccia, R., Bonechi, F., Francalanci, I., Abbate, R. & Gensini, G.F. (1989) Evaluation of new methods for the selective measurement of fibrin and fibrinogen degradation products. Thrombosis Research, 56, 547551.
  • Samama, M.M., Cohen, A.T., Darmon, J.Y., Desjardins, L., Eldor, A., Janbon, C., Leizorovicz, A., Nguyen, H., Olsson, C.G., Turpie, A.G. & Weisslinger, N. (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with enoxaparin study group. New England Journal of Medicine, 341, 793800.
  • De La Serna, J., Montesinos, P., Vellenga, E., Rayon, C., Parody, R., Leon, A., Esteve, J., Bergua, J.M., Milone, G., Deben, G., Rivas, C., Gonzalez, M., Tormo, M., Az-Mediavilla, J., Gonzalez, J.D., Negri, S., Amutio, E., Brunet, S., Lowenberg, B. & Sanz, M.A. (2008) Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood, 111, 33953402.
  • Shorr, A.F., Trotta, R.F., Alkins, S.A., Hanzel, G.S. & Diehl, L.F. (1999) D-dimer assay predicts mortality in critically ill patients without disseminated intravascular coagulation or venous thromboembolic disease. Intensive Care Medicine, 25, 207210.
  • Siegal, T., Seligsohn, U., Aghai, E. & Modan, M. (1978) Clinical and laboratory aspects of disseminated intravascular coagulation (DIC): a study of 118 cases. Journal of Thrombosis and Haemostasis, 39, 122134.
  • Sivula, M., Tallgren, M. & Pettila, V. (2005) Modified score for disseminated intravascular coagulation in the critically ill. Intensive Care Medicine, 31, 12091214.
  • Spero, J.A., Lewis, J.H. & Hasiba, U. (1980) Disseminated intravascular coagulation. Findings in 346 patients. Journal of Thrombosis and Haemostasis, 43, 2833.
  • Taylor, F.B.J., Chang, A., Esmon, C.T., D’Angelo, A., Vigano-D’Angelo, S. & Blick, K.E. (1987) Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. Journal of Clinical Investigation, 79, 918925.
  • Taylor, F.B., Jr, , Toh, C.H., Hoots, W.K., Wada, H. & Levi, M. (2001) Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis., 86, 13271330.
  • Toh, C.H. & Dennis, M. (2003) Disseminated intravascular coagulation: old disease, new hope. BMJ, 327, 974977.
  • Toh, C.H. & Hoots, W.K. (2007) The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview. Journal of Thrombosis and Haemostasis, 5, 604606.
  • Toh, C.H., Downey, C. & Dwyre, L. (2000) Thromboplastin sensitivity in waveform analysis. Journal of Thrombosis and Haemostasis, 84, 517518.
  • Wada, H., Wakita, Y., Nakase, T., Shimura, M., Hiyoyama, K., Nagaya, S., Mori, Y. & Shiku, H. (1995) Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Mie DIC Study Group. Journal of Thrombosis and Haemostasis, 74, 848852.
  • Warren, B.L., Eid, A., Singer, P., Pillay, S.S., Carl, P., Novak, I., Chalupa, P., Atherstone, A., Penzes, I., Kubler, A., Knaub, S., Keinecke, H.O., Heinrichs, H., Schindel, F., Juers, M., Bone, R.C. & Opal, S.M. (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA, 286, 18691878.
  • Wilde, J.T., Kitchen, S., Kinsey, S., Greaves, M. & Preston, F.E. (1989) Plasma D-dimer levels and their relationship to serum fibrinogen/fibrin degradation products in hypercoagulable states. British Journal of Haematology, 71, 6570.
  • Zuckerman, L., Cohen, E., Vagher, J.P., Woodward, E. & Caprini, J.A. (1981) Comparison of thrombelastography with common coagulation tests. Journal of Thrombosis and Haemostasis, 46, 752756.